Pharma Focus Asia

UCB faces U.S. patent challenge for epilepsy drug

Tuesday, May 24, 2016

The U.S. Patent and Trademark Office has begun a trial into whether Belgian pharmaceutical company UCB's patent for an epilepsy drug is valid, said a generic drug company that is challenging UCB's claim.

U.S. pharma group Argentum Pharmaceuticals said in a statement that it had been granted petition by the U.S. PTO for a review against all claims of the sole remaining patent of UCB's Vimpat drug.

The PTO had also established a "reasonable likelihood that it would prevail" in showing that certain claims made by UCB in the patent are "unpatentable", Argentum said.

UCB said it was aware of the development and that this had not changed its view that its patent for Vimpat, which had sales last year of 679 million euros ($758.7 million), was valid and would be upheld.

 

Source : reuters.com

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024